The morality of human subject research

(Medical Xpress) -- The federal government is in the process of revising the regulations that govern most human subject research in the United States.

In a “Policy Forum” piece in the Aug. 3 issue of Science, bioethics expert Rebecca Dresser, JD, the Daniel Noyes Kirby Professor of Law and professor of ethics in medicine at Washington University in St. Louis, weighs in with recommendations for changes in the oversight process.
Dresser writes that the research oversight system must be based on a fundamental moral judgment. “Human subjects have interests that should not be subordinated to the interests of the patients, researchers, industry stakeholders, and others who gain health and monetary benefits from the research enterprise,” she writes.

Dresser makes three recommendations:

  • To promote informed choice, researchers should adopt procedures to evaluate whether prospective subjects understand essential facts about a study.
  • Because research subjects accept burdens so that others may benefit, research sponsors and institutions should cover the costs of any study-related injuries.
  • To ensure that risks to subjects are justified by the importance of the knowledge a study is expected to produce (this is an existing regulatory requirement), studies should undergo independent and rigorous merit review.
Dresser holds a joint appointment at the law school and at Washington University School of Medicine in St. Louis, teaching law and medical students about legal and ethical issues in end-of-life care, biomedical research, genetics, assisted reproduction and related topics.

She has written extensively in her field and is the co-author of a casebook on bioethics and law and a book on the ethical treatment of animals. She also is the author of a book on patient advocacy and research ethics. Her most recent work is as editor and contributor to Malignant: Medical Ethicists Confront Cancer (Oxford University Press, 2012).

She is a member of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH) and a past member of the President’s Council on Bioethics. She also sits on the Washington University Medical Center Institutional Review Board, as well as the Washington University Embryonic Stem Cell Research Oversight Committee and Alzheimer’s Disease Research Center Ethics Committee.

More information: To view an abstract of the article, visit www.sciencemag.org/content/337/6094/527 .

Related Stories

Better ethics education needed in community-based research

May 03, 2012

A growing number of health research programs are collaborating with community groups to conduct research. The groups help recruit study participants, obtain informed consent, collect data and provide input on study design ...

Researchers weigh in on ethics of H5N1 research

Feb 09, 2012

(Medical Xpress) -- In a commentary on the biosecurity controversy surrounding publication of bird flu research details, a bioethicist and a vaccine expert at Johns Hopkins reaffirm that "all scientists have an affirmativ ...

Stem cell research from an ethical point of view

Jun 25, 2008

Stem cell research and the potential use of human embryonic stem cells in clinical therapy is a controversial issue which splits both scientific and public opinion. The current conflict over embryonic stem cells throughout ...

Recommended for you

Doctor behind 'free radical' aging theory dies

Nov 25, 2014

Dr. Denham Harman, a renowned scientist who developed the most widely accepted theory on aging that's now used to study cancer, Alzheimer's disease and other illnesses, has died in Nebraska at age 98.

Mexican boy who had massive tumor recovering

Nov 25, 2014

An 11-year-old Mexican boy who had pieces of a massive tumor removed and who drew international attention after U.S. officials helped him get treatment in the southwestern U.S. state of New Mexico is still recovering after ...

New medical device to make the mines safer

Nov 21, 2014

Dehydration can be a serious health issue for Australia's mining industry, but a new product to be developed with input from Flinders University's Medical Device Partnering Program (MDPP) is set to more effectively ...

US family gets $6.75 million in Botox case

Nov 20, 2014

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.